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Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has
remained marginal and GBM is still universally fatal with short survival times after initial
diagnosis. Much research is focused on finding new therapeutics for GBM and immune-
based approaches have shown great promise. The detection of cytomegalovirus (CMV)
antigens in malignant cells has suggested that treatment strategies based on immuno-
logical intervention, such as adoptive transfer of antiviral T cells or vaccination with viral
epitopes, could be exploited as cancer therapy. Here, we review the rationale for using
CMV as a therapeutic target and discuss the first clinical evidence for safety and efficacy
of CMV-specific cellular immunotherapy for GBM.
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INTRODUCTION
Temozolomide was the last drug to bring a significant improve-
ment of survival for patients with glioblastoma multiforme (GBM)
brain cancer (1). Now, almost a decade later, further major
advances in drug development have remained elusive. GBM
continues to be the most aggressive human brain cancer with
5 year survival rates below 10% (2). Standard of care treatment
includes surgical resection followed by radiation and chemother-
apy, however, even with optimal treatment median survival is only
15 months (1). Glioblastomas are incurable and inevitably recur
with a median survival of only 6 months (3). There is an urgent
need to find novel therapeutic targets and develop new treatment
strategies. Immune-based approaches have great potential, in par-
ticular, because they have the great advantage of being safer and
less toxic than chemotherapy drugs (4). Bevacizumab (brand name
Avastin) is the only immunotherapy drug currently approved for
the treatment of recurrent GBM. Bevacizumab is a monoclonal
antibody that blocks vascular endothelial growth factor (VEGF),
thereby reducing angiogenesis. Recently, two large clinical studies
evaluating bevacizumab for the treatment of primary GBM indi-
cated a prolonged progression free survival but failed to show a
significant benefit for overall survival (5, 6). Glioblastomas are
very heterogeneous tumors and it is likely that a single agent
will be insufficient to achieve therapeutic benefit in a majority of
patients. More than 30 studies are currently underway to assess the
potential of combination therapies using bevacizumab together
with radiation or other chemotherapy drugs (7). Most cellular
immunotherapies for GBM under investigation at the moment
focus on using tumor lysate loaded dendritic cells (DCs) or vacci-
nation using tumor peptides [for an overview see recent review in
Ref. (4)]. Preliminary results have shown some promise, however,
further optimization is needed to improve anti-tumor immune
responses.
CYTOMEGALOVIRUS AS A TARGET FOR GBM
IMMUNOTHERAPY
The first report of detection of cytomegalovirus (CMV) anti-
gens in histological sections of GBM (8) was received with much
controversy. Subsequent studies have disputed (9–11) as well as
confirmed (12–14) the original finding. While CMV sequences
have been detected in GBM tissues (15, 16), the topic contin-
ues to be controversial as recent deep sequencing studies fail to
detect CMV in GBM (17, 18). Interestingly, a clinical study evalu-
ating vaccination using DCs pulsed with autologous tumor lysate
described a patient that developed enhanced CMV-specific T cell
responses after one dose of the vaccine. No such response was
found in a patient with a CMV negative tumor enrolled into
the same study, which provided the first immunological evidence
for the presence of CMV antigens in glioma cells (19). Spe-
cific killing of primary GBM cells by autologous CMV-specific
T cells was demonstrated recently and further argues for the exis-
tence of CMV antigens in brain tumors (20). The precise role
of CMV in GBM remains unclear. In contrast to other mem-
bers of the herpes virus family like Epstein–Barr virus, CMV is
not an oncogenic virus. However, CMV encodes many genes that
may enable hallmarks of cancer such as pro-angiogenic signal-
ing, immune evasion, and deregulation of the cell cycle (21–26).
From a therapeutic perspective, the presence of CMV antigens
provides a unique opportunity to exploit pre-existing antiviral
immunity for immune-based GBM treatment. Further support
for this rationale stems from the finding that lower levels of
CMV antigens in GBM sections are associated with prolonged
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survival (27, 28). Therapeutic use of antiviral drug valganciclovir
for GBM patients has been explored without major side effects, but
further studies are needed to assess efficacy (29–31). In the con-
text of immunotherapy, a previous study of CMV-specific T cell
responses in GBM patients has detected functional impairment
of antiviral T cells. Despite similar frequencies in GBM patients
and healthy individuals, CMV-specific cytotoxic T cells in GBM
patients showed limited ability to produce multiple cytokines
(macrophage inflammatory protein MIP-1β, tumor necrosis fac-
tor TNF, interferon IFNγ) and to mobilize CD107a in response
to CMV epitopes (32). Importantly, polyfunctionality of CMV-
specific T cells isolated from GBM patients could be restored by
in vitro stimulation with CMV antigens and γC cytokines (32).
This suggests that adoptive transfer of in vitro expanded T cells
could improve CMV-specific immune responses in GBM patients.
Indeed, this preliminary study has shown that immunotherapy
using CMV-specific T cells was coincident with prolonged survival
in one patient (32). CMV-specific immunity is characterized by
high frequencies of CMV-specific cytotoxic T cells in seropositive
individuals. While tumor associated antigens are usually poorly
immunogenic, viral antigens provide a strong stimulus that makes
expansion of high-frequency antiviral T cell cultures compar-
atively easy. Consequently, several laboratories have established
efficient protocols for the in vitro expansion of CMV-specific cyto-
toxic T cells from GBM patients for the purpose of immunother-
apy (20, 32, 33). Efficient killing of autologous primary tumor cells
by CMV-specific T cells was demonstrated in vitro, thus, providing
direct evidence that CMV-specific cytotoxic T cells can be applied
for GBM therapy (20).
CURRENT INVESTIGATIONS OF CYTOMEGALOVIRUS
SPECIFIC GBM IMMUNOTHERAPY
Two clinical studies using CMV-specific immunotherapy are cur-
rently recruiting participants and two further studies using CMV-
specific autologous lymphocyte transfer and DC vaccination have
completed enrollment (Table 1). Of the currently recruiting stud-
ies, one study is testing genetically modified CMV-specific cyto-
toxic cells for the treatment of recurrent GBM (clinical trials
identifier NCT01109095). CMV-specific T cells are engineered to
express a chimeric antigen receptor (CAR) recognizing human
epidermal growth factor receptor 2 (HER-2) coupled to CD28
(7). HER-2 antigen is expressed on a majority of GBM cells
and CD28 promotes sustained T cell activity. While the primary
objective of the study is safety, it might provide some insight if
the targeting of glioma cells using T cells specific for CMV and
HER-2 can provide a survival benefit. The second CMV-specific
GBM immunotherapy under investigation is based on a combi-
nation of DC vaccination and a monoclonal antibody directed
against CD25, which blocks interleukin IL-2 signaling (clinical
trials identifier NCT00626483). Autologous DCs are loaded with
CMV pp65-LAMP mRNA and administered with different doses
of CD25 antibody, which is expected to inhibit regulatory T cells
(7, 34). In this approach, alleviating the suppressive effect of reg-
ulatory T cells might lead to more efficient CMV-specific T cell
activity. Results from these studies are expected by 2016 and 2015,
respectively.
FIRST CLINICAL OUTCOMES OF CYTOMEGALOVIRUS
SPECIFIC THERAPY FOR GBM
The first formal clinical assessment of CMV-specific adoptive
T cell immunotherapy was completed recently (35). Ten CMV
seropositive patients with recurrent GBM received three or four
infusions of autologous CMV-specific cytotoxic T cells generated
following in vitro stimulation with synthetic CMV epitopes. The
treatment was shown to be safe and only mild side effects were
recorded. While the patient cohort was too small to draw def-
inite conclusions about efficacy and effects on overall survival,
it is notable that 4 out of 10 patients remained completely dis-
ease free during the study period. At present, the follow up time
for these patients since initiation of T cell therapy ranges from
10 months to more than 4 years, which extends well beyond the
expected survival median time of 6 months after tumor recur-
rence. Immunological and molecular analysis revealed a number
of important insights. Analysis of a range of immunological para-
meters on peripheral blood mononuclear cells (PBMC) before
and after T cell therapy failed to reveal major changes. In contrast,
molecular analysis of the T cell product used for adoptive ther-
apy showed a signature of seven genes (EOMES, IFNG, BCL6,
XAF1, CCL5, CTLA-4, FOXP3) that distinguished individuals
with long-term progression free survival from patients that pro-
gressed more rapidly. This signature was consistent with T cell
activation (i.e., upregulation of T cell transcription factor Eomes
and effector molecule IFNγ, downregulation of inhibitory recep-
tor CTLA-4) suggesting that more functional CMV-specific T
cells are more efficient in controlling cancer relapse. One patient
had a tumor recurrence after therapy and isolation of T cells
Table 1 | Current clinical trials evaluating CMV-specific immunotherapy for GBM.
Intervention GBM type Enrollment Phase Duration NCT number Status
Genetically modified HER.CAR CMV-specific CTLs Recurrent 18 I 2010–2031 NCT01109095 Recruiting
DC vaccine (CMV pp65-LAMP mRNA loaded DC), basiliximab
(anti-CD25)
Primary 18 I 2007–2015 NCT00626483 Recruiting
DC vaccine (CMV pp65-LAMP mRNA loaded DC) with or without
autologous lymphocyte transfer, tetanus toxoid
Primary 16 I 2006–2016 NCT00639639 Active, not
recruiting
CMV autologous lymphocyte transfer with or without DC vaccine (CMV
pp65-LAMP mRNA loaded DC)
Primary 12 I 2008–2016 NCT00693095 Active, not
recruiting
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from the resected tissue revealed the first evidence that CMV-
specific T cells are present in tumor tissues. In addition, intra-
tumoral T cells were found to express higher levels of immune
inhibitory molecules, indicating that local immunosuppression
might be an important factor in the development of effective
therapies.
IMMUNE REGULATORY MECHANISMS TO CONSIDER
Immunosuppression is one of the classic hallmarks of human
cancers (36). In the context of GBM, this principle applies locally in
the tumor microenvironment as well as systemically (4). Immune
inhibitory receptors expressed on T cells such as PD-1, CTLA-
4, TIM-3, or BTLA play an important role for modulation of
T cell responses. Expression of PD-L1, the ligand for PD-1, has
been detected in glioma samples (37) and a recent study found
high-PD-L1 levels in tumor tissue to be associated with poor
survival (38). Blockade of such checkpoint inhibitors might there-
fore be an attractive treatment option to boost intrinsic tumor
defenses. Interference with the PD-1/PD-L1 interaction by mono-
clonal antibodies directed against PD-1 is currently under clinical
investigation for the treatment of recurrent GBM (clinical tri-
als identifier NCT01952769). Similarly, a monoclonal antibody
blocking CTLA-4 (ipilimumab) that is currently approved for the
treatment of metastatic melanoma might be effective in enhanc-
ing anti glioma immune responses. A combination therapy of
anti-VEGF and anti-PD-1 or anti-CTLA-4 is in phase II testing
for recurrent GBM (clinical trials identifier NCT02017717). In
the context of CMV-specific immunotherapy for GBM, analysis
of intratumoral CMV-specific T cells in a patient that relapsed
after T cell therapy indicated that local immunosuppression might
have contributed to treatment failure (35). While further test-
ing is needed to confirm this finding in a larger patient cohort,
it is tempting to speculate that combination of CMV-specific T
cells with blockade of inhibitory receptors might boost efficacy of
adoptive immunotherapy.
CONCLUSION AND PERSPECTIVE
Immunotherapies provide a novel approach to complement stan-
dard therapies for GBM treatment (Figure 1). CMV antigens
provide an attractive target for cellular immunotherapies that
FIGURE 1 | Adoptive immunotherapy as an addition to standard
treatment for GBM patients. GBM patients receive standard of care therapy
consisting of surgery followed by chemo- and radiotherapy. However, tumor
recurrence is inevitable. In GBM patients, who are CMV seropositive,
virus-specific T cell immunotherapy can be used as consolidative treatment to
enhance intrinsic immune responses against viral antigen expressing tumor
cells. If effective, adoptive immunotherapy has the potential to prolong
progression free survival or even prevent relapse in GBM patients.
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could provide more efficient tumor recognition than tumor asso-
ciated antigens. The first clinical assessment of CMV-specific
T cell therapy has been completed and proved to be safe
with potential clinical benefit. Further clinical trials using CMV
directed immunotherapy for GBM are underway. Cancer associ-
ated immunosuppression has to be taken into account as it might
limit the effectiveness of antiviral T cells within the tumor tissue.
Future studies should therefore focus on multimodal strategies
combining cellular immunotherapy with blockage of inhibitory
receptors on T cells.
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